
|Articles|January 1, 2003
Innovate, integrate, and treat
Las Vegas - Much of what is new in dermatologic therapy represents off-label use of marketed drugs, but clinicians should not let that fact necessarily deter them from prescribing what may be very safe and effective therapy, said Stephen Stone, M.D., at the Fall Clinical Dermatology Conference.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
3
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5














